Goldman Urology Clinic has recorded a cumulative total of 6,000 surgeries for benign prostatic hyperplasia (BPH), demonstrating the strength of its patient-centered treatment system. The clinic attributes this milestone to treatment strategies that consider prostate size, symptom severity, and recovery planning in a comprehensive manner.
Benign prostatic hyperplasia is widely recognized as a common condition among middle-aged and older men. As the prostate enlarges excessively, it compresses the urethra and leads to lower urinary tract symptoms such as frequent urination, nocturia, a sensation of incomplete bladder emptying, and delayed urination. In the early stages, symptoms can often be managed with medication. However, when the response to medication declines or symptoms repeatedly worsen, surgical treatment may become necessary. In such cases, it is important to consider not only the size and shape of the prostate but also the patient’s symptoms, the presence of complications, underlying chronic diseases, anesthesia considerations, and recovery planning in order to guide patients toward the most appropriate treatment method.
Based on these principles, Goldman Urology Clinic has focused on introducing advanced surgical techniques and refining clinical protocols. These include Rezūm therapy, which injects high-temperature steam into the prostate to cause necrosis and shrink enlarged tissue; Aquablation, a robotic waterjet surgery that uses high-pressure water guided by an AI-based system to precisely remove prostate tissue without thermal damage; and Holmium Laser Enucleation of the Prostate (HoLEP), which removes enlarged prostate tissue using a holmium laser.
The clinic also offers additional treatment options such as the iTind device, which expands the prostatic urethra, and the UroLift system, which minimizes the burden associated with traditional surgical tissue removal. By offering multiple treatment approaches, the clinic has developed a personalized treatment strategy tailored to each patient’s prostate size, anatomical structure, and symptom severity.
In addition, Goldman Urology Clinic continues to conduct research on benign prostatic hyperplasia based on more than two million accumulated clinical cases collected over more than 20 years. These research efforts have translated into clinical outcomes in real-world practice and have received positive recognition. For example, the clinic has presented research findings related to robotic waterjet surgery at academic conferences and has continuously evaluated and refined the safety and effectiveness of new surgical techniques in real clinical settings.
Dr. Lee Chang-gi, CEO of Goldman Urology Clinic, explained that the outcomes of BPH surgery depend on several factors, including the experience of the medical team, the accuracy of preoperative evaluation, and the quality of postoperative management systems. He noted that physicians across all branches of Goldman Urology Clinic regularly share clinical data and collaborate to improve treatment protocols, enhancing consistency and safety in patient care.
He also emphasized that benign prostatic hyperplasia affects patients differently. Because the symptoms, accompanying medical conditions, and recovery plans vary from person to person, it is not appropriate to rely on a single treatment method as the universal solution. Instead, he explained, the core principle is to recommend the most suitable procedure at the appropriate time according to each patient’s condition and treatment needs.